CYP450 Enzyme Inducers vs Inhibitors: How to Tell Them Apart
CYP450 enzyme inducers and inhibitors are both drug-interaction phenomena that alter the hepatic metabolism of substrate drugs, and both are heavily tested through interaction vignettes (classically warfarin and phenytoin). The core axis that separates them is direction: inducers increase enzyme activity and lower substrate drug levels, while inhibitors decrease enzyme activity and raise substrate drug levels.
How to tell them apart
| Feature | CYP450 Enzyme Inducers | CYP450 Enzyme Inhibitors |
|---|---|---|
| Effect on CYP450 | Increase enzyme activity | Decrease enzyme activity |
| Result on substrate drug levels | Decreased levels of substrate drugs (faster metabolism) | Increased levels of substrate drugs (slower metabolism) |
| Onset | Delayed — days to weeks, because it requires new enzyme protein synthesis | Rapid — occurs quickly through direct binding to the enzyme |
| Clinical action needed | May need to increase the substrate drug dose to maintain efficacy | May need to decrease the substrate drug dose to avoid toxicity |
| Effect on warfarin/INR | Accelerates warfarin metabolism → decreased INR (subtherapeutic) | Slows warfarin metabolism → warfarin accumulation → elevated INR (e.g., fluconazole inhibits CYP2C9) |
| Effect on phenytoin levels | Induces CYP2C9 → accelerated metabolism → subtherapeutic phenytoin levels | Inhibits CYP2C9 → slowed metabolism → phenytoin accumulation and toxicity (ataxia, nystagmus) |
| Key examples | Rifampin, carbamazepine, phenytoin, phenobarbital, griseofulvin, chronic alcohol, St. John's wort | Ketoconazole, fluconazole, erythromycin/clarithromycin, cimetidine, fluoxetine, isoniazid, omeprazole, metronidazole, grapefruit juice |
The reasoning
Anchor on the direction of change in the substrate drug's level or effect. If a stable patient becomes subtherapeutic after a new drug is added (falling phenytoin level, dropping INR), suspect enzyme induction; if they develop toxicity (rising INR, phenytoin toxicity with ataxia and nystagmus), suspect enzyme inhibition. Use the timing to arbitrate: inhibition is rapid because the drug binds the enzyme directly, whereas induction is delayed for days to weeks because it depends on synthesis of new enzyme protein. Finally, match the offending agent to its category — inducers like rifampin, carbamazepine, and phenobarbital lower levels, while inhibitors like fluconazole, fluoxetine, and ketoconazole raise them.
Key tests
- INR in a patient on warfarin: falls (subtherapeutic) with an inducer, rises (e.g., 6.2) with an inhibitor such as fluconazole
- Serum phenytoin level: drops (e.g., from 15 to 6 mcg/mL) with an inducer causing subtherapeutic levels; rises (e.g., to 35 mcg/mL with ataxia/nystagmus) with an inhibitor such as fluoxetine
- Substrate drug serum concentration trend after adding a new agent: decreasing levels point to induction, increasing levels point to inhibition — with induction manifesting over days to weeks and inhibition appearing rapidly
What they share
- Both act on the CYP450 (cytochrome P450) enzyme system and alter the metabolism of co-administered substrate drugs
- Both are clinically critical for narrow-therapeutic-index drugs such as warfarin and phenytoin, where small changes in metabolism produce large clinical consequences
- Both may require dose adjustment of the affected substrate drug to maintain therapeutic levels
Pitfalls
- Phenytoin can appear on BOTH lists — it is itself a CYP inducer, yet its own levels are exquisitely sensitive to inhibitors; because of its zero-order (saturable) kinetics, even modest inhibition causes disproportionate accumulation and toxicity
- Alcohol is a trap: chronic alcohol use induces CYP450, whereas acute alcohol intoxication inhibits it
- Expecting an immediate effect from an inducer — because induction requires protein synthesis, subtherapeutic levels may not appear for days to weeks, unlike the rapid effect of inhibitors
- Confusing protein-binding displacement with metabolic interactions — when one drug displaces another from plasma proteins (e.g., valproate displacing phenytoin), protein binding decreases and the free (active) fraction transiently rises, while the total measured level often falls or stays unchanged as the freed drug is cleared; this is a distinct mechanism from enzyme induction and is not what drives induction-related subtherapeutic levels
- Overlooking grapefruit juice, which inhibits intestinal CYP3A4 and raises bioavailability of substrates like statins, calcium channel blockers, and cyclosporine
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.